


## Supporting Information (S6 Fig)


### (A) Urine output

	Ranking (mean)	SUCRA
Placebo	6.4	0.1
Tolvaptan 7.5mg	6.5	0.1
Tolvaptan 15mg	5	0.3
Tolvaptan 30mg	2.8	0.7
Tolvaptan 45mg	2.7	0.7
Tolvaptan 60mg	1.8	0.9
Tolvaptan 90mg	2.9	0.7




(B) Body weight change

	Ranking (mean)	SUCRA
— Placebo	6.2	0.1
— Tolvaptan 7.5mg	6.8	0
— Tolvaptan 15mg	5	0.3
— Tolvaptan 30mg	4	0.5
— Tolvaptan 45mg	2.2	0.8
— Tolvaptan 60mg	2.3	0.8
— Tolvaptan 90mg	1.6	0.9




(C) Change of serum sodium

	Ranking (mean)	SUCRA
Placebo	7	0
Tolvaptan 7.5mg	3.8	0.5
Tolvaptan 15mg	5.9	0.2
Tolvaptan 30mg	4.2	0.5
Tolvaptan 45mg	2.5	0.7
Tolvaptan 60mg	2.1	0.8
Tolvaptan 90mg	2.5	0.7




(D) Mortality

	Ranking (mean)	SUCRA
— Placebo	3.5	0.4
— Tolvaptan 15mg	3.2	0.5
— Tolvaptan 30mg	2.7	0.6
— Tolvaptan 60mg	4.2	0.2
— Tolvaptan 90mg	1.5	0.9




(E) Thirsty

	Ranking (mean)	SUCRA
— Placebo	1.1	1
— Tolvaptan 7.5mg	3.2	0.6
— Tolvaptan 15mg	2.8	0.7
— Tolvaptan 30mg	5	0.3
— Tolvaptan 45mg	6.8	0
— Tolvaptan 60mg	5	0.3
— Tolvaptan 90mg	4.2	0.5




(F) Renal failure

	Ranking (mean)	SUCRA
Placebo	5.3	0.3
Tolvaptan 7.5mg	1.3	1
Tolvaptan 15mg	5.1	0.3
Tolvaptan 30mg	4.9	0.3
Tolvaptan 45mg	3.3	0.6
Tolvaptan 60mg	3.1	0.7
Tolvaptan 90mg	5	0.3



(G) Incidence of all adverse effects



**S6 Fig. Ranking Probability of Strategies and Surface under the Cumulative Curve in the Network Meta-analysis of tolvaptan dosage strategies for CHF patients**